echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: New progress in immunotherapy!

    ASCO 2021: New progress in immunotherapy!

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 4, 2021, the annual event of the global oncology community-the American Society of Clinical Oncology ( ASCO ) annual meeting officially kicked off.


    ASCO clinical trial digestion

    RATIONALE 302 study is the digestive tract tumor areas first global Phase 3 study as a Leading PI by Chinese researchers, is the first global phase 3 study esophageal squamous cell carcinoma, the data brisk performance, this year's ASCO concern of the research project One.


    RATIONALE 302 study is the digestive tract tumor areas first global Phase 3 study as a Leading PI by Chinese researchers, is the first global phase 3 study esophageal squamous cell carcinoma, the data brisk performance, this year's ASCO concern of the research project One.


    The tumor


    Reference
    1, International Agengy for Research on Cancer in 2018, WHO data cancer today.
    https://gco.
    iarc.
    fr/today/explore
    2, People’s Republic of China Health Commission.
    Esophageal Cancer Diagnosis and Treatment Specifications (2018 Edition) Diagnosis and Treatment
    3 , Zhang T, et al.
    Cancer Immunol Immunother.
    2018;67(7):1079-1090
    4, Yingcai Feng, et al.
    AACR.
    2019; Volume 79, Issue 13 Supplement, pp.
    2383
    5, Abstract #4048 American Association for Cancer Research March 29-April 3,2019, Atlanta, GA.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.